Preconditioning of stem cells for the treatment of myocardial infarction

Chinese Medical Journal

Volumn 125, Issue 2, 2012, Pages 378-384

  Lu, Hui He ^a   Li, Yi Fei ^a   Sheng, Zheng Qiang ^a   Wang, Yi ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Myocardial infarction; Preconditioning; Stem cells

Indexed keywords

DIAZOXIDE; GROWTH FACTOR; WORTMANNIN;

CELL DEATH; CELL HYPOXIA; CELL PROTECTION; CELL SURVIVAL; DNA MODIFICATION; GENE OVEREXPRESSION; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; INFLAMMATION; MICROENVIRONMENT; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; VASCULARIZATION;

HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84862954811     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.02.037     Document Type: Review

References (78)

1. Koh GY, Klug MG, Soonpaa MH, Field LJ. Differentiation and longterm survival of C2C12 myoblast grafts in heart. J Clin Invest 1993; 92: 1548-1554.
2. Koh GY, Soonpaa MH, Klug MG, Field LJ. Long-term survival of AT-1 cardiomyocyte grafts in syngeneic myocardium. Am J Physiol 1993; 264: H1727-H1733.
3. Farahmand P, Lai TY, Weisel RD, Fazel S, Yau T, Menasche P, et al. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation 2008; 118: S130-S137.
4. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006; 203: 2315-2327.
5. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009; 120: 408-416.
6. Strauer BE, Ott G, Schannwell CM, Brehm M. Bone marrow cells to improve ventricular function. Heart 2009; 95: 98-99.
7. Tateishi K, Takehara N, Matsubara H, Oh H. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med 2008; 12: 2217-2232.
8. Dawn B, Abdel-Latif A, Sanganalmath SK, Flaherty MP, Zuba-Surma EK. Cardiac repair with adult bone marrow-derived cells: The clinical evidence. Antioxid Redox Signal 2009; 11: 1865-1882.
9. Haider HKh, Tan AC, Aziz S, Chachques JC, Sim EK. Myoblast transplantation for cardiac repair: A clinical perspective. Mol Ther 2004; 9: 14-23.
10. Anversa P, Leri A, Kajstura J. Cardiac regeneration. J Am Coll Cardiol 2006; 47: 1769-1776.
11. Nadal-Ginard B, Anversa P, Kajstura J, Leri A. Cardiac stem cells and myocardial regeneration. Novartis Found Symp 2005; 265: 142-154.
12. Abdul Kadir SH, Ali NN, Mioulane M, Brito-Martins M, Abu-Hayyeh S, Foldes G, et al. Embryonic stem cell-derived cardiomyocytes as a model to study fetal arrhythmia related to maternal disease. J Cell Mol Med 2009; 13: 3730-3741.
13. Winkler J, Hescheler J, Sachinidis A. Embryonic stem cells for basic research and potential clinical applications in cardiology. Biochim Biophys Acta 2005; 1740: 240-248.
14. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007; 204: 405-420.
15. Azarnoush K, Maurel A, Sebbah L, Carrion C, Bissery A, Mandet C, et al. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J Thorac Cardiovasc Surg 2005; 130: 173-179.
16. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
17. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; 1: 39-49.
18. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
19. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009; 27: 543-549.
20. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41: 879-888.
21. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-98.
22. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 2000; 9: 489-502.
23. Baldi A, Abbate A, Bussani R, Patti G, Melfi R, Angelini A, et al. Apoptosis and postinfarction left ventricular remodeling. J Mol Cell Cardiol 2002; 34: 165-174.
24. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106: 2881-2883.
25. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: Priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 2000; 32: 881-889.
26. Logue SE, Gustafsson AB, Samali A, Gottlieb RA. Ischemia/reperfusion injury at the intersection with cell death. J Mol Cell Cardiol 2005; 38: 21-23.
27. Camirand G, Caron NJ, Turgeon NA, Rossini AA, Tremblay JP. Treatment with anti-CD154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. Transplantation 2002; 73: 453-461.
28. Hodgetts SI, Grounds MD. Complement and myoblast transfer therapy: Donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5. Immunol Cell Biol 2001; 79: 231-239.
29. Hodgkinson CP, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther 2010; 21: 1513-1526.
30. Makkar RR, Price MJ, Lill M, Frantzen M, Takizawa K, Kleisli T, et al. Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 2005; 10: 225-233.
31. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
32. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-983.
33. Baines CP, Pass JM, Ping P. Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning. Basic Res Cardiol 2001; 96: 207-218.
34. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 2000; 9: 489-502.
35. Konstantinov IE, Arab S, Li J, Coles JG, Boscarino C, Mori A. The remote ischemic preconditioning stimulus modifies gene expression in mouse myocardium. J Thorac Cardiovasc Surg 2005; 130: 1326-1332.
36. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106: 2881-2883.
37. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: Evidence suggesting cross-species protection. Clin Sci (Lond) 2009; 117: 191-200.
38. Zhao ZQ, Vinten-Johansen J. Postconditioning: Reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70: 200-211.
39. Gross GJ, Auchampach JA. Blockade of ATP sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
40. Xu M, Wang Y, Ayub A, Ashraf M. Mitochondrial K(ATP) channel activation reduces anoxic injury by restoring mitochondrial membrane potential. Am J Physiol Heart Circ Physiol 2001; 281: H1295-H1303.
41. Patel HH, Gross ER, Peart JN, Hsu AK, Gross GJ. Sarcolemmal KATP channel triggers delayed ischemic preconditioning in rats. Am J Physiol Heart Circ Physiol 2005; 288: H445-H447.
42. Budas GR, Churchill EN, Mochly-Rosen D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res 2007; 55: 523-536.
43. Ravingerová T, Matejíková J, Neckár J, Andelová E, Kolár F. Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart. Mol Cell Biochem 2007; 297: 111-120.
44. Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation 2005; 111: 1114-1120.
45. Addya S, Shiroto K, Turoczi T, Zhan L, Kaga S, Fukuda S, et al. Ischemic preconditioningmediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice. J Mol Cell Cardiol 2005; 38: 345-351.
46. Hu X, Dai S, Wu WJ, Tan W, Zhu X, Mu J, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac stromal cell derived factor-1alpha CXCR4 axis. Circulation 2007; 116: 654-663.
47. Niagara MI, Haider HKh, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555.
48. Kubo M, Li TS, Suzuki R, Shirasawa B, Morikage N, Ohshima M, et al. Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance. Am J Physiol Heart Circ Physiol 2008; 294: H590-H595.
49. Rosová I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26: 2173-2182.
50. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009; 104: 1209-1216.
51. Kis B, Nagy K, Snipes JA, Rajapakse NC, Horiguchi T, Grover GJ, et al. The mitochondrial K(ATP) channel opener BMS-191095 induces neuronal preconditioning. Neuroreport 2004; 15: 345-349.
52. Niagara MI, Haider HKh, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555.
53. O'Sullivan JC, Yao XL, Alam H, McCabe JT. Diazoxide, as a postconditioning and delayed preconditioning trigger, increases HSP25 and HSP70 in the central nervous system following combined cerebral stroke and hemorrhagic shock. J Neurotrauma 2007; 24: 532-546.
54. Wang Y, Takashi E, Xu M, Ayub A, Ashraf M. Downregulation of protein kinase C inhibits activation of mitochondrial K(ATP) channels by diazoxide. Circulation 2001; 104: 85-90.
55. Afzal MR, Haider HKh, Idris NM, Jiang S, Ahmed RP, Ashraf M. Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in the infarcted heart via NF-kappaB signaling. Antioxid Redox Signal 2010; 12: 693-702.
56. Mahboubi K, Biedermann BC, Carroll JM, Pober JS. IL-11 activates human endothelial cells to resist immune-mediated injury. J Immunol 2000; 164: 3837-3846.
57. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008; 77: 134-142.
58. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, et al. Stromal cell-derived factor-1a promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008; 324: 834-849.
59. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28: 644-650.
60. Shintani S, Kusano K, Ii M, Iwakura A, Heyd L, Curry C, et al. Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Clin Pract Cardiovasc Med 2006; 3: S123-S128.
61. Kutschka I, Kofidis T, Chen IY, von Degenfeld G, Zwierzchoniewska M, Hoyt G, et al. Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation 2006; 114: I174-I180.
62. Bartunek J, Croissant JD, Wijns W, Gofflot S, de Lavareille A, Vanderheyden M, et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 2007; 292: H1095-H1104.
63. Shmelkov SV, Meeus S, Moussazadeh N, Kermani P, Rashbaum WK, Rabbany SY, et al. Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissue. Circulation 2005; 111: 1175-1183.
64. Nakamura T, Schneider MD. The way to a human's heart is through the stomach: Visceral endoderm-like cells drive human embryonic stem cells to a cardiac fate. Circulation 2003; 107: 2638-2639.
65. Lu G, Haider HK, Jiang S, Ashraf M. Sca-1+ stem cell survival and engraftment in the infarcted heart: Dual role for preconditioninginduced connexin-43. Circulation 2009; 119: 2587-2596.
66. Dzau VJ, Gnecchi M, Pachori AS. Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol 2005; 46: 1351-1353.
67. Matsumoto R, Omura T, Yoshiyama M, Hayashi T, Inamoto S, Koh KR, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005; 25: 1168-1173.
68. Yau TM, Kim C, Ng D, Li G, Zhang Y, Weisel RD, et al. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg 2005; 80: 1779-1786.
69. Haider HKh, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008; 103: 1300-1308.
70. Kanemitsu N, Tambara K, Premaratne GU, Kimura Y, Tomita S, Kawamura T, et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model. J Heart Lung Transplant 2006; 25: 1253-1262.
71. Kofidis T, de Bruin JL, Yamane T, Balsam LB, Lebl DR, Swijnenburg RJ, et al. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 2004; 22: 1239-1245.
72. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004; 109: 2454-2461.
73. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110: 3300-3305.
74. Elmadbouh I, Haider HK, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42: 792-803.
75. Shmelkov SV, Meeus S, Moussazadeh N, Kermani P, Rashbaum WK, Rabbany SY, et al. Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissue. Circulation 2005; 111: 1175-1183.
76. Nakamura Y, Yasuda T, Weisel RD, Li RK. Enhanced cell transplantation: Preventing apoptosis increases cell survival and ventricular function. Am J Physiol Heart Circ Physiol 2006; 291: H939-H947.
77. Jiang S, Haider HKh, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006; 99: 776-784.
78. DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004; 298: 167-177.